Benitec Biopharma to Participate in Upcoming Investor Conferences in December
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference platform, has announced their participation in two upcoming investor conferences in December 2024.
The company will participate in the Piper Sandler Annual Healthcare Conference on December 4, 2024, at 12:00 PM EST in New York, featuring a fireside discussion and one-on-one meetings. Additionally, they will attend the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, from 9:50-10:40 AM EST in New York, participating in a panel discussion and one-on-one meetings.
Benitec Biopharma (NASDAQ: BNTC), un'azienda biotecnologica in fase clinica focalizzata sulla terapia genica e nello sviluppo di medicinali genetici utilizzando la loro piattaforma proprietaria di interferenza RNA diretta da DNA 'Silence and Replace', ha annunciato la propria partecipazione a due conferenze per investitori che si svolgeranno a dicembre 2024.
L'azienda parteciperà alla Piper Sandler Annual Healthcare Conference il 4 dicembre 2024, alle 12:00 PM EST a New York, con una discussione informale e incontri one-on-one. Inoltre, parteciperanno al Oppenheimer Movers in Rare Disease Summit il 12 dicembre 2024, dalle 9:50 alle 10:40 AM EST a New York, partecipando a una tavola rotonda e incontri one-on-one.
Benitec Biopharma (NASDAQ: BNTC), una empresa de biotecnología en etapa clínica centrada en la terapia génica y el desarrollo de medicamentos genéticos utilizando su plataforma propietaria de interferencia de ARN dirigida por ADN 'Silence and Replace', ha anunciado su participación en dos conferencias para inversores en diciembre de 2024.
La empresa participará en la Piper Sandler Annual Healthcare Conference el 4 de diciembre de 2024, a las 12:00 PM EST en Nueva York, con una discusión informal y reuniones uno a uno. Además, asistirán al Oppenheimer Movers in Rare Disease Summit el 12 de diciembre de 2024, de 9:50 a 10:40 AM EST en Nueva York, participando en una mesa redonda y reuniones uno a uno.
베니텍 바이오파마 (NASDAQ: BNTC)는 유전자 치료와 고유의 '침묵 및 교체' DNA-유도 RNA 간섭 플랫폼을 이용한 유전 의약품 개발에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 12월에 예정된 두 개의 투자자 컨퍼런스에 참여한다고 발표하였습니다.
회사는 2024년 12월 4일 오후 12시 EST에 뉴욕에서 개최되는 파이퍼 샌들러 연례 헬스케어 컨퍼런스에 참여하여 비공식 논의 및 일대일 미팅을 진행할 예정입니다. 또한, 2024년 12월 12일 오전 9시 50분부터 10시 40분까지 EST에 뉴욕에서 열리는 오펜하이머 희귀 질병 서밋에 참석하여 패널 토론 및 일대일 미팅에 참여할 것입니다.
Benitec Biopharma (NASDAQ: BNTC), une entreprise de biotechnologie en phase clinique axée sur la thérapie génique et le développement de médicaments génétiques utilisant leur plateforme propriétaire d'interférence ARN dirigée par ADN 'Silence and Replace', a annoncé sa participation à deux conférences pour investisseurs en décembre 2024.
L'entreprise participera à la Piper Sandler Annual Healthcare Conference le 4 décembre 2024, à 12h00 EST à New York, avec une discussion informelle et des réunions individuelles. De plus, elle assistera au Oppenheimer Movers in Rare Disease Summit le 12 décembre 2024, de 9h50 à 10h40 EST à New York, participant à une discussion en panel et à des réunions individuelles.
Benitec Biopharma (NASDAQ: BNTC), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Gentherapie und die Entwicklung genetischer Medikamente mit ihrer proprietären 'Silence and Replace'-DNA-gesteuerten RNA-Interferenz-Plattform konzentriert, hat ihre Teilnahme an zwei bevorstehenden Investorenkonferenzen im Dezember 2024 bekannt gegeben.
Das Unternehmen wird am 4. Dezember 2024 um 12:00 Uhr EST an der Piper Sandler Annual Healthcare Conference in New York teilnehmen, die eine informelle Diskussion und Einzelgespräche umfasst. Zusätzlich werden sie am 12. Dezember 2024 von 9:50 bis 10:40 Uhr EST am Oppenheimer Movers in Rare Disease Summit in New York teilnehmen und an einer Podiumsdiskussion sowie Einzelgesprächen mitwirken.
- None.
- None.
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences.
Piper Sandler Annual Healthcare Conference
Date: December 4, 2024
Time of Fireside Discussion: 12:00 PM EST
Location: New York, NY
Format: Fireside Discussion & 1x1 Meetings
The Benitec presentation will also be available via live webcast here.
Oppenheimer Movers in Rare Disease Summit
Date: December 12, 2024
Time of Fireside Chat: 9:50-10:40 AM EST
Location: New York, NY
Format: Panel discussion & 1x1 Meetings
Please contact your conference representative to schedule a 1x1 meeting with Benitec management.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
What investor conferences will Benitec Biopharma (BNTC) attend in December 2024?
When is Benitec Biopharma's (BNTC) presentation at the Piper Sandler Healthcare Conference?
What type of technology platform does Benitec Biopharma (BNTC) use?
